Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S100B | P04271 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 14/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 8/20 | 0.41 |
| ▸ | MEN1 | O00255 | 7/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.41 |
| ▸ | HPGD | P15428 | 6/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 9/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.39 |
| ▸ | GFER | P55789 | 2/20 | 0.39 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 4/20 | 0.37 |
| ▸ | GLA | P06280 | 4/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31265588 | 0.84 | S100B (0.46) | S100BALDH1A1L3MBTL1MEN1KMT2A | |
| SCHEMBL31265585 | 0.84 | S100B (0.46) | S100BALDH1A1L3MBTL1MEN1KMT2A | |
| SCHEMBL3105597 | 0.84 | NSD2 (0.36) | ALDH1A1L3MBTL1MEN1KMT2AHPGD | |
| SCHEMBL150569 | 0.82 | S100B (0.50) | S100BALDH1A1L3MBTL1MEN1KMT2A | |
| SCHEMBL150568 | 0.78 | S100B (0.51) | S100BALDH1A1L3MBTL1MEN1KMT2A | |
| SCHEMBL8014237 | 0.75 | S100B (0.59) | S100BALDH1A1L3MBTL1MEN1KMT2A | |
| SCHEMBL128645 | 0.74 | S100B (0.47) | S100BALDH1A1L3MBTL1MEN1KMT2A | |
| SCHEMBL10346490 | 0.74 | S100B (0.54) | S100BALDH1A1L3MBTL1MEN1KMT2A | |
| Sulfuric Acid SCHEMBL7955346 | 0.74 | S100B (0.80) | S100BALDH1A1L3MBTL1MEN1KMT2A | |
| SCHEMBL8943409 | 0.74 | ALDH1A1 (0.48) | S100BALDH1A1L3MBTL1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11116772-B2 | Medical methods utilising high purity diaminophenothiazinium compounds | WISTA LABORATORIES LTD. (SG) | 2021-09-14 | — | — | US | disclosed |
| US-20200268767-A1 | MEDICAL METHODS UTILISING HIGH PURITY DIAMINOPHENOTHIAZINIUM COMPOUNDS | WISTA LABORATORIES LIMITED (SG) | 2020-08-27 | — | — | US | disclosed |
| EP-3564223-A1 | METHODS OF CHEMICAL SYNTHESIS AND PURIFICATION OF DIAMINOPHENOTHIAZINIUM COMPOUNDS INCLUDING METHYLTHIONINIUM CHLORIDE (MTC) | WisTa Laboratories Ltd. (SG) | 2019-11-06 | — | — | EP | disclosed |
| EP-2322517-B1 | METHODS OF CHEMICAL SYNTHESIS AND PURIFICATION OF DIAMINOPHENOTHIAZINIUM COMPOUNDS INCLUDING METHYLTHIONINIUM CHLORIDE (MTC) | WISTA LAB LTD (SG) | 2019-04-24 | — | — | EP | disclosed |
| US-20180078562-A1 | MEDICAL METHODS UTILISING HIGH PURITY DIAMINOPHENOTHIAZINIUM COMPOUNDS | WISTA LABORATORIES LTD. (SG) | 2018-03-22 | — | — | US | disclosed |
| US-9801890-B2 | Medical methods utilising high purity diaminophenothiazinium compounds | WISTA LABORATORIES LTD. (SG) | 2017-10-31 | — | — | US | disclosed |
| US-20170209456-A1 | Methods of chemical synthesis and purification of diaminophenothiazinium compounds including methylthioninium chloride (MTC) | WISTA LABORATORIES LTD. (SG) | 2017-07-27 | — | — | US | disclosed |
| US-9555043-B2 | High purity diaminophenothiazinium compounds including methylthioninium chloride (MTC) | WISTA LABORATORIES LTD. (SG) | 2017-01-31 | — | — | US | disclosed |
| US-20160129009-A1 | HIGH PURITY DIAMINOPHENOTHIAZINIUM COMPOUNDS INCLUDING METHYLTHIONINIUM CHLORIDE (MTC) | WISTA LABORATORIES LTD. (SG) | 2016-05-12 | — | — | US | disclosed |
| US-9242946-B2 | High purity diaminophenothiazinium compounds including methylthioninium chloride (MTC) | WISTA LABORATORIES LTD. (SG) | 2016-01-26 | — | — | US | disclosed |
| CN-103012315-A | Chemical synthesis and purification of diaminophenothiazinium compounds including methylene blue (MTC) | WISTA LAB LTD | 2013-04-03 | — | — | CN | disclosed |
| CN-101084204-B | Chemical synthesis and purification of diaminophenothiazinium compounds including methylene blue (MTC) | WISTA LAB LTD | 2012-12-05 | — | — | CN | disclosed |
| EP-2322517-A1 | Methods of chemical synthesis and purification of diaminophenothiazinium compounds including methylthioninium chloride (MTC) | Wista Laboratories Ltd. (SG) | 2011-05-18 | — | — | EP | disclosed |
| US-20110021510-A1 | METHODS OF CHEMICAL SYNTHESIS AND PURIFICATION OF DIAMINOPHENOTHIAZINIUM COMPOUNDS INCLUDING METHYLTHIONINIUM CHLORIDE (MTC) | WISTA LABORATORIES LTD. | 2011-01-27 | — | — | US | disclosed |
| US-7790881-B2 | Methods of chemical synthesis and purification of diaminophenothiazinium compounds including methylthioninium chloride (MTC) | WISTA LABORATORIES LTD. (SG) | 2010-09-07 | — | — | US | disclosed |
| US-20080207603-A1 | Methods of Chemical Synthesis and Purification of Diaminophenothiazinium Compounds Including Methylthioninium Chloride (Mtc) | WISTA LABORATORIES LTD. | 2008-08-28 | — | — | US | disclosed |
| CN-101084204-A | Methods for chemical synthesis and purification of diaminophenothiazinium compounds, including methylthioninium chloride (MTC) | WISTA LAB LTD (SG) | 2007-12-05 | — | — | CN | disclosed |
| EP-1799662-A2 | METHODS OF CHEMICAL SYNTHESIS AND PURIFICATION OF DIAMINOPHENOTHIAZINIUM COMPOUNDS INCLUDING METHYLTHIONINIUM CHLORIDE (MTC) | Wista Laboratories Ltd. (SG) | 2007-06-27 | — | — | EP | disclosed |
| WO-2006032879-A2 | METHODS OF CHEMICAL SYNTHESIS AND PURIFICATION OF DIAMINOPHENOTHIAZINIUM COMPOUNDS INCLUDING METHYLTHIONINIUM CHLORIDE (MTC) | WISTA LABORATORIES LTD. (SG) | 2006-03-30 | — | — | WO | disclosed |
| US-4962197-A | Photo-inactivation of cancer cells | ROWLAND INSTITUTE FOR SCIENCE (US) | 1990-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11116772-B2 | Medical methods utilising high purity diaminophenothiazinium compounds | MGMT, MAPT, TST | S100B 67/4885ALDH1A1 3409/4885L3MBTL1 3969/4885 |
| US-20160129009-A1 | HIGH PURITY DIAMINOPHENOTHIAZINIUM COMPOUNDS INCLUDING METHYLTHIONINIUM CHLORIDE (MTC) | MGMT, TST, MAPT | S100B 193/4885ALDH1A1 3982/4885L3MBTL1 3620/4885 |
| US-20080207603-A1 | Methods of Chemical Synthesis and Purification of Diaminophenothiazinium Compounds Including Methylthioninium Chloride (Mtc) | MGMT, MAPT, CRBN | S100B 64/4885ALDH1A1 3952/4885L3MBTL1 1757/4885 |
| US-20170209456-A1 | Methods of chemical synthesis and purification of diaminophenothiazinium compounds including methylthioninium chloride (MTC) | MGMT, TST, MAPT | S100B 176/4885ALDH1A1 3846/4885L3MBTL1 3626/4885 |
| US-20180078562-A1 | MEDICAL METHODS UTILISING HIGH PURITY DIAMINOPHENOTHIAZINIUM COMPOUNDS | MGMT, MAPT, TST | S100B 77/4885ALDH1A1 3735/4885L3MBTL1 4142/4885 |
| US-20110021510-A1 | METHODS OF CHEMICAL SYNTHESIS AND PURIFICATION OF DIAMINOPHENOTHIAZINIUM COMPOUNDS INCLUDING METHYLTHIONINIUM CHLORIDE (MTC) | MGMT, TST, MAPT | S100B 180/4885ALDH1A1 3694/4885L3MBTL1 3662/4885 |
| US-20200268767-A1 | MEDICAL METHODS UTILISING HIGH PURITY DIAMINOPHENOTHIAZINIUM COMPOUNDS | MGMT, MAPT, TST | S100B 77/4885ALDH1A1 3735/4885L3MBTL1 4142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.